J Asthma Allergy, 2020, 13(2020):757-772

The Role of Heat Shock Protein 70 kDa in Asthma

Asthma is a complex chronic disorder of the airways, affecting immune and structural cells and inducing both protein and tissue remodeling. Heat shock proteins 70 kDa (HSP70s) are highly conserved members of the stress-induced family, possessing precisely described chaperone activity. There is growing evidence of a tight relationship between inflammatory diseases of different origins and the elevation of local HSP70 expression and secretion. Although extracellular HSP70 does not serve as a common marker of asthma, elevated HSP70 levels have been detected in the peripheral blood serum and sputum of patients with asthma, as well as in the bronchoalveolar lavage fluid of mice with induced allergic airway inflammation. Possessing diverse immunomodulating properties, extracellular HSP70 can manifest different activities in airway inflammatory processes and asthma, acting either as a pro-inflammatory trigger, or an anti-inflammatory agent. This review will discuss the effects and possible mechanisms concerning HSP70 implication in airway inflammation regulation in asthma. We examine ATPase and chaperone activities of HSP70 as potential modulators of immune responses in asthma. Given the crucial role of a chronic inflammatory response in asthma, understanding the effects of HSP70 on immune and structural cells may reveal new perspectives for the therapeutic control of inflammation.

IBCH: 9035
Ссылка на статью в журнале: https://www.dovepress.com/articles.php?article_id=60851
Кол-во цитирований на 07.2026: 27
Данные статьи проверены модераторами 2021-01-13

Список научных проектов, где отмечена публикация

  1. -Поиск ключевых гуморальных и клеточных факторов, отвечающих за переключение с нейтрофил- на эозинофил-опосредованный иммунный ответ, при аллергическом воспалении дыхательных путей (July 1, 2020 — June 30, 2022). Servuli E.A.. Grant, RSF.
  2. -Направленная доставка белков теплового шока HSP70 к раковым клеткам как новый подход к противоопухолевой иммунотерапии (July 1, 2019 — June 30, 2022). Kanevskiy L.M.. Grant, RSF.